Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.

Publication

Citation
Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015
Authors
Ebiike H, Kawada H, Koyama K, Morikami K, Nakamura M, Ogawa K, Ohwada J., Shinma N, Tsukazaki M, Tsukuda T, Yamamoto S, Yoshida M, Yoshinari K
Journal
Bioorg Med Chem
Year
2015
PubMed
26613634
Machine-readable
REST APIRDF
Palacky University Olomouc

Palacky University Olomouc

Faculty of Science

Department of Physical Chemistry

tř. 17. listopadu 1192/12

771 46 Olomouc

Czech Republic

How to cite?

Juračka J., Šrejber M., Melíková M., Bazgier V., Berka K.: MolMeDB: Molecules on Membranes Database. Database, Volume 2019, 2019, baz078, https://doi.org/10.1093/database/baz078

Follow us

FacebookGithub

Financial Support

  • MolMeDB interoperability with UniProt and SwissLipids – MEYS Czech-Swiss project ELIXIR-IMPACT 8K0208 (2026–2028)
ELIXIRGAČRUP Olomouc
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. | MolMeDB